학술논문
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Document Type
Journal
Author
Krebs, Matthew; Brunsvig, Paal; Helland, Aslaug; Vinolas Segarra, Nuria; Ponce Aix, Santiago; Carcereny Costa, Enric; Domine Gomez, Manuel; Trigo Perez, Jose Manuel; Arriola, Edurne; Garcia Campelo, Rosario; Spicer, James; Thompson, Jonathan; Ortega Granados, Ana Laura; Holt, Robert; Lorens, James; Shoaib, Muhammad; Siddiqui, Abdul; Schmidt, Emmett; Chisamore, Michael; Felip, Enriqueta
Source
Subject
Language
English
ISSN
20511426